Amorphous Solid Dispersion — An Ideal Formulation Approach to Improve Developability of Poorly Soluble Molecules

Discover an informative webinar uncovering the transformative impact of amorphous solid dispersion on drug solubility. Aqueous solubility results in low bioavailability and developability issues. Various approaches such as salt formation, solubilization using a co-solvent, complexation with cyclodextrin and particle size reduction have limitations for their wide applicability for all molecules.

Amorphous solid dispersion is one of the most promising approaches that not only helps overcome the limitations of these other approaches but also helps enhance the bioavailability and enable compounds to toxicity studies. The solid dispersion approach has unique advantages in terms of its applicability for a wide range of molecules, safety of vehicles and scalability.

In this webinar, Sreehari Babu, Sr. Vice President — Formulations Solutions at Aragen Life Sciences, will deep dive into how amorphous solid dispersion is an ideal approach for poorly soluble drug substances and demonstrate how Aragen can offer end-to-end solutions from screening to good manufacturing practice (GMP) supplies through technology overview and case studies.

Join this webinar to learn how amorphous solid dispersion revolutionizes drug solubility, addressing aqueous solubility challenges for enhanced bioavailability and pharmaceutical development.

Speaker

Sreehari Babu Putchakayala, SVP & Head, Formulation Development Solutions, Aragen

Sreehari Babu Putchakayala has over 20 years of experience in pharmaceutical development, with 14 years in leadership roles covering early phase, drug discovery support, product development in drug discovery R&D, generics formulation development and clinical supplies management. Sreehari previously worked with Novartis Pharmaceuticals, Ranbaxy Research Laboratories and Dr. Reddy’s Laboratories.

Message Presenter